The shares of Bristol-Myers Squibb Company (NYSE:BMY) has been pegged with a rating of Buy by Societe Generale in its latest research note that was published on January 15th, 2019. Societe Generale wasn’t the only research firm that published a report of Bristol-Myers Squibb Company, with other equities research analysts also giving their opinion on the stock. Citigroup advised investors in its research note published on October 22nd, 2018, to Neutral the BMY stock. The stock had earned Neutral rating from Guggenheim when it published its report on October 9th, 2018. The stock was given Neutral rating by Atlantic Equities in its report released on August 8th, 2018. Morgan Stanley was of a view that BMY is Equal-Weight in its latest report on April 17th, 2018. Citigroup thinks that BMY is worth Buy rating. This was contained in the firm’s report on April 12th, 2018 in which the stock’s price target was also moved to $70.

Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 8 believe it has the potential for further growth, thus rating it as Hold while 4 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $56.73. The price of the stock the last time has raised by 14.90% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 50.07.

The shares of the company dipped by -0.95% during the trading session on Monday, reaching a low of $50.54 while ending the day at $50.90. During the trading session, a total of 13.96 million shares were traded which represents a 22.78% incline from the average session volume which is 18.08M shares. BMY had ended its last session trading at 51.39. Bristol-Myers Squibb Company currently has a market cap of $83.30B, while its P/E ratio stands at 16.75, while its P/E earnings growth sits at 3.69, with a beta of 0.80. Bristol-Myers Squibb Company debt-to-equity ratio currently stands at 0.52, while its quick ratio hovers at 1.50. BMY 52-week low price stands at $44.30 while its 52-week high price is $68.22.

The company in its last quarterly report recorded $0.94 earnings per share which is above the $0.85 predicted by most analysts. The Bristol-Myers Squibb Company generated $5,973.00 million in revenue during the last quarter, which is slightly lower than the $5,985.40 million predicted by analysts. In the second quarter last year, the firm recorded $1.09 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -15.96%. Bristol-Myers Squibb Company has the potential to record 3.04 EPS for the current fiscal year, according to equities analysts.

Investment analysts at Vertical Research published a research note on February 4th, 2019 where it informed investors and clients that Delta Air Lines, Inc. (NYSE:DAL) is now rated as Hold. Citigroup also rated DAL as Downgrade on October 22nd, 2018, with its price target of $115 suggesting that DAL could surge by 17.2% from its current share price. Even though the stock has been trading at $49.59/share, analysts expect it to surge higher by 3.09% to reach $61.74/share. It started the day trading at $51.285 and traded between $49.77 and $51.12 throughout the trading session.

A look at its technical shows that DAL’s 50-day SMA is 49.42 while its 200-day SMA stands at 53.33. The stock has a high of $61.32 for the year while the low is $45.08. The company’s P/E ratio currently sits at 9.01, while the P/B ratio is 2.54. At the moment, only of Delta Air Lines, Inc. shares were sold short. The company’s average trading volume currently stands at 8.14M shares, which means that the short-interest ratio is just 2.10 days. Over the past seven days, the company moved, with its shift of 4.78%. Looking further, the stock has dropped -11.98% over the past 90 days while it lost -9.43% over the last six months.

The Vanguard Group Inc meanwhile bought more DAL shares in the recently filed quarter, changing its stake to $2,370,016,107 worth of shares. PRIMECAP Management Co followed the path by decreasing its DAL portfolio by -0.35% in the quarter. This means that PRIMECAP Management Co sold -99,985 shares in the last quarter and now controls 28,455,026 shares of the DAL stock, with the valuation hitting $1,406,531,935.

Similarly, Lansdowne Partners decreased its Delta Air Lines, Inc. shares by -3.55% during the recently filed quarter. After selling -933,950 shares in the last quarter, the firm now controls 25,402,084 shares of Delta Air Lines, Inc. which are valued at $1,255,625,012. In the same vein, SSgA Funds Management Inc decreased its Delta Air Lines, Inc. shares by during the most recent reported quarter. The firm sold -546,043 shares during the quarter which decreased its stakes to 21,300,028 shares and is now valued at $1,052,860,384. Following these latest developments, around 0.30% of Delta Air Lines, Inc. stocks are owned by institutional investors and hedge funds.